Keros Therapeutics (KROS) said Tuesday it has agreed to provide Takeda Pharmaceutical (TAK) with a global commercial license for elritercept, as well as to collaborate on the drug candidate's development.
Keros said it expects to receive an upfront payment of $200 million, with milestone payments that could reach up to $1.1 billion. It also expects to receive tiered royalties on net sales.
The upfront payment would extend Keros' operational runway through Q4 of 2028, the company said.
The agreement is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act, Keros said.
Elritercept is currently in late-stage clinical trials for myelodysplastic syndrome and myelofibrosis, according to Keros.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。